Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

#160; Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries.  The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.   Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products. 

Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development.  

Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 44 billion units annually.  Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.

Forward-Looking Statement Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release.  For instance, any statements in this press release concerning prospe
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... England , July 22, 2014 ... development and device company focused on solid dose ... its novel solid formulation of octreotide acetate achieved ... it with the currently marketed liquid product (Sandostatin®). ... transfer the formulation production process to a contract ...
(Date:7/21/2014)... /PRNewswire-iReach/ -- Nitrosolution.com, a website that features safe and ... first anniversary in August. The online retailer specializes in ... body,s ability to produce nitric oxide. Called Nitroxyl, it ... a variety of phytonutrients and other natural ingredients that ... nitric oxide production in the arteries and ...
(Date:7/21/2014)... , July 21, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... operating results for the second quarter of fiscal year ... will hold a conference call to discuss its financial ... at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern ...
Breaking Medicine Technology:Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2Thoratec Schedules Second Quarter Conference Call, Webcast 2
... 12 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... drug (IND) application to the U.S. Food and ... for rheumatoid,arthritis and other autoimmune conditions. The initial ... a double-blind, randomized,placebo-controlled, ascending single-dose study in healthy ...
... Medical Lasers Limited,(ASX: ELX), a global leader in ... systems, announced today initial clinical results of,an ongoing ... demonstrate the therapy,s potential to improve and,stabilize visual ... with,diabetic maculopathy and macular edema without causing any ...
Cached Medicine Technology:Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 2Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 4
(Date:7/22/2014)... One of the largest studies ever conducted into the ... new sites on chromosomes that harbor inherited genes tied ... team of researchers, now bring the total number of ... Although these schizophrenia-associated genes aren,t specific enough ... will or will not develop the illness, researchers say ...
(Date:7/22/2014)... July 22, 2014 CarePoint Health is pleased ... as the President of the medical staff at Bayonne Medical ... serve as President, as voted on by the physicians on ... medical staff in relation to the administration at Bayonne Medical ... physicians and to work to make the Medical Center the ...
(Date:7/22/2014)... The donation from the Edusei Foundation was greatly ... a feat of strategic engineering, such assistance tends to etch ... the beneficiaries. It provided a sense of family to them, ... Edusei Foundation donated various amounts of; milk, soap, ... , The Government of Ghana established the Kumasi Children’s Home ...
(Date:7/22/2014)... 2014 Hospitals & Health ... conducted by Hospitals & Health Networks in ... CareTech Solutions, The College of Healthcare Information ... list recognizes hospitals for successful health information ... in four focus areas: business and administrative ...
(Date:7/22/2014)... TUESDAY, July 22, 2014 (HealthDay News) -- People who ... risk for a rise in blood pressure, a new ... major health problems and even early death, but few ... trouble may be one of the causes, according to ... 138 people who had been separated or divorced for ...
Breaking Medicine News(10 mins):Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2Health News:Edusei Foundation Donates Food and Needed Items to Kumasi Children’s Home in Ashanti Region of Ghana 2Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 2Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 3Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 4Health News:Sleepless Nights After Divorce May Be Tied to Blood Pressure Rise 2
... The Association for Research in Vision and Ophthalmology ... distinguished fellows. The title of Fellow of ARVO (FARVO) ... the Association. By accepting this honor, ARVO anticipates ... and mentors for individuals pursuing careers in vision and ...
... be important in cardiac development has been newly associated ... the left ventricular outflow tract. These are the findings ... appearing in the journal Birth Defects Research Part ... including aortic valve stenosis, coarctation of the aorta, hypoplastic ...
... tomography (PET) in patients with head and neck tumours, ... cannot currently be reliably assessed. This is the result ... for Quality and Efficiency in Health Care (IQWiG). The ... to assess the advantages and disadvantages of this diagnostic ...
... prostate-rectal inter-space is an effective way to reduce the ... according to research presented April 30, 2011, at the ... symposium is sponsored by the American Society for Radiation ... Even though prostate cancer is cured in over 90 ...
... Combining computerized tomography (CT) with fluorodeoxyglucose positron emission ... tumor outlines and potentially different treatment options in ... CT alone, according to research presented today, at ... Atlanta. This symposium is co-sponsored by the American ...
... of hospitalization have discouraged primary care doctors from seeing ... use of "hospitalists," a new physician specialty focused on ... field mean that frequently hospitalized patients also may need ... expert on hospital care at the University of Chicago. ...
Cached Medicine News:Health News:2011 ARVO Fellows announced 2Health News:Study identifies second gene associated with specific congenital heart defects 2Health News:Benefit of PET in patients with head and neck tumors cannot be assessed 2Health News:Benefit of PET in patients with head and neck tumors cannot be assessed 3Health News:Benefit of PET in patients with head and neck tumors cannot be assessed 4Health News:Tissue spacers reduce risk of rectal injury for prostate cancer patients 2Health News:Frequently hospitalized patients may benefit from new medical specialty focused on their needs 2
... To aid clinicians in performing Ankle/Brachial ... a new, complete packet of information. It ... presentation that can be viewed on any ... the step-by-step procedure of performing an ABI ...
... Auto Refractor/Keratometer. Advanced engineering, ... retro illumination mode make it the ... use. 5.5 inch High Quality ... focusing. Rapid, instantaneous readings are taken ...
... for Urinary Tract Infection (UTI) ... A multi-center study was conducted ... UTIs. There were 1,887 urine ... and nitrite results of Multistix ...
... PocketChem UA is the first ... take up valuable lab bench space. ... the variability in results between operators ... on every run, corrects for ambient ...
Medicine Products: